Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score

Adjuvant chemotherapy is beneficial for premenopausal women-and not postmenopausal women-with HR-positive, HER2-negative, early breast cancer with 1-3 lymph nodes and a recurrence score of 0-25, according to updated results from the phase III RxPonder study.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963289/
https://www.ncbi.nlm.nih.gov/pubmed/35348778
http://dx.doi.org/10.1093/oncolo/oyac012
_version_ 1784677959363198976
author Jacobson, Anne
author_facet Jacobson, Anne
author_sort Jacobson, Anne
collection PubMed
description Adjuvant chemotherapy is beneficial for premenopausal women-and not postmenopausal women-with HR-positive, HER2-negative, early breast cancer with 1-3 lymph nodes and a recurrence score of 0-25, according to updated results from the phase III RxPonder study.
format Online
Article
Text
id pubmed-8963289
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89632892022-03-29 Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score Jacobson, Anne Oncologist Conference Perspectives: Highlights from SABCS Adjuvant chemotherapy is beneficial for premenopausal women-and not postmenopausal women-with HR-positive, HER2-negative, early breast cancer with 1-3 lymph nodes and a recurrence score of 0-25, according to updated results from the phase III RxPonder study. Oxford University Press 2022-03-28 /pmc/articles/PMC8963289/ /pubmed/35348778 http://dx.doi.org/10.1093/oncolo/oyac012 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Conference Perspectives: Highlights from SABCS
Jacobson, Anne
Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
title Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
title_full Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
title_fullStr Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
title_full_unstemmed Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
title_short Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
title_sort benefits of adjuvant chemotherapy differ by menopausal status in women with hr+/her2- early breast cancer, 1-3 positive nodes, and a low recurrence score
topic Conference Perspectives: Highlights from SABCS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963289/
https://www.ncbi.nlm.nih.gov/pubmed/35348778
http://dx.doi.org/10.1093/oncolo/oyac012
work_keys_str_mv AT jacobsonanne benefitsofadjuvantchemotherapydifferbymenopausalstatusinwomenwithhrher2earlybreastcancer13positivenodesandalowrecurrencescore

Ejemplares similares